Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.

John W Eikelboom,Jacqueline J Bosch,Stuart J Connolly,Olga Shestakovska,Gilles R Dagenais,Robert G Hart,Darryl P Leong,Martin O'Donnell,Keith A A Fox,Deepak L Bhatt,John A Cairns,Christoph Tasto,Scott D Berkowitz, Nancy Cook Bruns,Eva Muehlhofer,Rafael Diaz,Aldo P Maggioni,Salim Yusuf

Journal of the American College of Cardiology（2019）

引用 30|浏览73

暂无评分

摘要

The combination of rivaroxaban and aspirin compared with aspirin alone increased major bleeding, mainly from the GI tract. Most excess bleeding occurred during the first year after randomization, was of mild or moderate intensity, and was managed with conventional supportive therapy. (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease [COMPASS]; NCT01776424).

查看译文

关键词

aspirin,bleeding,coronary artery disease,dual pathway,peripheral artery disease,rivaroxaban

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要